Lucian Ionescu
Lucian Ionescu joined UCB in 2006, and since then, has contributed to building the immunology franchise through a track record of strategic and operational leadership roles, in Global Brand Leadership (Cimzia Pre/Launch and Commercial Implementation), Strategic Projects and Early Medicines (Bimzelx Early Development), Medical and Clinical Affairs, Global Corporate, in Europe and the United States. He built twice medical affairs organizations (Global and US), and acted as a global project leader for two launches, in rheumatology Cimzia NR axSpA and dermatology Cimzia PsO. Lucian combines passion for science with translation into patient value. He is versatile in understanding the commercial processes, marketplace dynamics, stakeholders, ecosystems, towards integration and decision-making for value creation holistically.
Lucian is a Medical Doctor (MD), and before joining UCB, has worked as a clinician in Romania, and as a scientist at University of Pennsylvania. Over his 22 yrs of professional career, he published in multiple scientific journals; he holds an MBA from Vlerick Business School, a top-100-business school, and executive degrees from Wharton, MIT, Insead and IMD (Executive Management, Artificial Intelligence and Business Strategy).
Since Sep 2019, Lucian leads the European Immunology Commercial Operations at UCB, and is responsible for evolving the business from one biologic/one therapeutic area to a portfolio of biologics across three therapeutic areas (rheumatology, dermatology, osteoporosis). Passionate about Digital Business Transformation, he and the team aspire to partner internally and externally towards contributing to digitizing and optimizing the health care system, while benefiting patients of innovative medicines across Europe during the next few years.
Exploring how the guidelines defines holistic care
Integrating holistic care through guideline recommendations with patient-reported outcomes and shared decision-making
Personalising the approach to HS care
Personalised HS care: Addressing the multi-faceted burden of HS with a case study example
Combination approaches in HS
The role of combined medical/surgical and medical-only treatments, including the optimal time for intervention
An overview of the European S2k guidelines
Key guideline updates including management algorithms for inflammatory and non-inflammatory HS phenotypes
Shared decisions: Redefining HS treatment
Prof. Prignano and Prof. Liakou discuss patient-reported outcomes, shared decision-making and multidisciplinary HS care
From guidelines to action: Transforming HS treatment pathways
Dr van der Zee and Prof. Arenbergerová explore holistic treatment of HS through medical, surgical and combined approaches